1. Sohn W, Lee YS, Kim SS, et al. KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025. Clin Mol Hepatol 2025;31 Suppl:S1–S31.
2. Oh JH, Ahn SB, Cho S, Nah EH, Yoon EL, Jun DW. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J Hepatol 2024;81:772–780.
4. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology 2024;79:1393–1400.
5. Ginès P, Serra-Burriel M, Kamath PS. Metabolic dysfunction-associated steatotic liver disease-the new epidemic of chronic liver disease. JAMA Netw Open 2025;8:e2516381.
6. Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2021;19:580–589.e5.
7. Owrangi S, Paik JM, Golabi P, et al. Meta-analysis: global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther 2025;61:433–443.
8. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249–1253.
9. Berzigotti A, Abraldes JG. Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. Gastroenterol Hepatol 2013;36:527–533.
10. Hagström H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut 2018;67:1536–1542.
12. Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol 2022;76:588–599.
13. Chen H, Yang C, Yan S, Liu X, Zhou L, Yuan X. Sarcopenia in cirrhosis: from pathophysiology to interventional therapy. Exp Gerontol 2024;196:112571.
16. Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci 2005;9:279–284.
17. Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther 2024;59 Suppl 1:S10–S22.
21. European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol 2019;70:172–193.
22. Liu Y, Ji F, Nguyen MH. Sarcopenia in cirrhosis: epidemiology, diagnosis, management and prognosis. Curr Opin Gastroenterol 2023;39:131–139.
23. Behiry ME, Mogawer S, Yamany A, et al. Ability of the short physical performance battery frailty index to predict mortality and hospital readmission in patients with liver cirrhosis. Int J Hepatol 2019;2019:8092865.
29. Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle 2016;7:126–135.
30. Nishikawa H, Nishiguchi S. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern Med 2016;55:855–856.
31. Merli M. Nutrition in cirrhosis: dos and don’ts. J Hepatol 2020;73:1563–1565.
32. Maki H, Yamanaka-Okumura H, Katayama T, et al. Late evening snacks with branched-chain amino acids improve the Fischer ratio with patients liver cirrhosis at fasting in the next morning. Clin Nutr ESPEN 2019;30:138–144.
33. Okamoto M, Sakaida I, Tsuchiya M, Suzuki C, Okita K. Effect of a late evening snack on the blood glucose level and energy metabolism in patients with liver cirrhosis. Hepatol Res 2003;27:45–50.
37. Razzak IA, Fares A, Stine JG, Trivedi HD. The role of exercise in steatotic liver diseases: an updated perspective. Liver Int 2025;45:e16220.
38. Zenith L, Meena N, Ramadi A, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1920–1926.e2.
39. García-Pagàn JC, Santos C, Barberá JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996;111:1300–1306.
41. Jamali T, Raasikh T, Bustamante G, et al. Outcomes of exercise interventions in patients with advanced liver disease: a systematic review of randomized clinical trials. Am J Gastroenterol 2022;117:1614–1620.
42. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089–2099.
45. Pestana L, Swain J, Dierkhising R, Kendrick ML, Kamath PS, Watt KD. Bariatric surgery in patients with cirrhosis with and without portal hypertension: a single-center experience. Mayo Clin Proc 2015;90:209–215.
47. Patton H, Heimbach J, McCullough A. AGA clinical practice update on bariatric surgery in cirrhosis: expert review. Clin Gastroenterol Hepatol 2021;19:436–445.
48. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299–310.